The Cardiorenal Syndrome: Pathophysiologic Crosstalk, Outcomes, and Treatment Targets

ISSN: 2212-4063 (Online)
ISSN: 1871-529X (Print)

Volume 17, 3 Issues, 2017

Download PDF Flyer

Cardiovascular & Hematological Disorders-Drug Targets

Formerly: Current Drug Targets - Cardiovascular & Hematological Disorders

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Submit Abstracts Online Submit Manuscripts Online

Garry X. Shen
University of Manitoba
Winnipeg, MB

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

The Cardiorenal Syndrome: Pathophysiologic Crosstalk, Outcomes, and Treatment Targets

Cardiovascular & Hematological Disorders-Drug Targets, 14(3): 170-176.

Author(s): Lisa Cohen.

Affiliation: Hospital Medicine, Duke University School of Medicine, P.O. Box 100800, Durham, NC 27705.


The development of simultaneous decompensation in cardiac and renal function is a common phenomenon in patients with congestive heart failure. Termed the cardiorenal syndrome (CRS), this joint deterioration in cardiac output and renal filtration is the result of a complex interplay of hemodynamic and neurohormonal factors. Recently, endothelial dysfunction, inflammation and uremia have been recognized as contributors to the crosstalk responsible for the development of CRS. Management strategies for the treatment of CRS involve correction of hemodynamic derangements and regulation of neurohormonal pathways. Future therapies may target more newly recognized components of CRS pathophysiologic development.


Cardiorenal syndrome, heart failure, kidney injury, renal failure, venous congestion, volume overload.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 14
Issue Number: 3
First Page: 170
Last Page: 176
Page Count: 7
DOI: 10.2174/1871529X14666140701100913
Price: $58

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science